Addiction

Bicycle Health & Wellpath Sign Additional 1-Year Contract with Federal Bureau of Prisons (FBOP) to Continue Opioid Use Disorder Treatment for Patients in Community Placements

This telehealth-based treatment program started in 2023 and has treated over 2600 patients, allowing them to continue treatment after release,...

Protega Pharmaceuticals collaborates with Wellgistics Health to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond™, is designed to provide multiple levels of protection PRINCETON, N.J., March 3, 2025...

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids,...

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

 New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders...

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2...

error: Content is protected !!